Comparative Pharmacology
Head-to-head clinical analysis: CO LAV versus POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO LAV versus POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES.
CO-LAV vs POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Polyethylene glycol 3350 is an osmotic laxative that acts by retaining water in the stool, increasing stool volume, and stimulating colonic peristalsis. Electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate) are included to maintain fluid and electrolyte balance and prevent shifts.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
4 liters of PEG-3350 and electrolytes solution orally as a single dose for colonoscopy preparation; alternative split-dose regimen: 2 liters evening before and 2 liters morning of procedure. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water once daily, up to 3 days.
None Documented
None Documented
Unknown
Not applicable; PEG 3350 is not metabolized and is eliminated non-kinetically. Clinical effect occurs during colonic transit; residual drug cleared within 24–48 hours post-dose.
CO-LAV is not a recognized drug. Please check the drug name.
Primarily fecal (unchanged); minimal renal excretion (<2%) as intact polymer. Electrolytes absorbed and renally excreted.
Category C
Category C
Laxative/Bowel Evacuant
Bowel Evacuant